Plasma levels of homocysteine in patients with white-coat hypertension

International Journal of Clinical Practice

Volumn 58, Issue 11, 2004, Pages 997-999

  Çoban, Erkan ^a   Ozdogan M ^a   Ermis C ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk; Hyperhomocysteinemia; White coat hypertension

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HOMOCYSTEINE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION;

ADULT; BIOLOGICAL MARKERS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 10444235085     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00013.x     Document Type: Article

References (15)

1. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002; 16: 391-9.
2. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
3. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep 2003; 5: 26-31.
4. Pickering TG, Coats A, Mallion JM et al. Blood pressure monitoring. Task force V. White-coat hypertension. Blood Press Monit 1999; 4: 333-41.
5. Pierdomenico SD, Bucci A, Costantini F et al. Twenty-four-hour autonomic nervous function in sustained and 'white coat' hypertension. Am Heart J 2000; 140: 672-7.
6. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998; 98: 1892-7.
7. Palatini P, Mormino P, Santonastoso M et al. Target-organ damage in stage 1 hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998; 31: 57-63.
8. Pierdomenico SD, Bucci A, Lapenna D et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-70.
9. Perna AF, Ingrosso D, Lombardi C et al. Homocysteine in Uremia. Am J Kidney Dis 2003; 41 (3 Suppl. 2): 123-6.
10. Woo KS, Qiao M, Chook P et al. Homocysteine, endothelial dysfunction, and coronary artery disease: emerging strategy for secondary prevention. J Card Surg 2002; 17: 432-5.
11. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156: 1105-13.
12. Araki A, Sako Y, Fukushima Y et al. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-46.
13. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-9.
14. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
15. van Dijk RA, Rauwerda JA, Steyn M et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 2072-9.